Orthopaedic regenerative tissue engineering en route to the holy grail: disequilibrium between the demand and the supply in the operating room

被引：25

作者：

Cengiz I.F. ^{[1
,2
]}

Pereira H. ^{[1
,2
,3
,4
]}

de Girolamo L. ^{[5
]}

Cucchiarini M. ^{[6
]}

Espregueira-Mendes J. ^{[1
,2
,7
,8
,9
]}

Reis R.L. ^{[1
,2
,10
]}

Oliveira J.M. ^{[1
,2
,7
,10
]}

机构：

[1] 3B’s Research Group, I3Bs – Research Institute on Biomaterials, Biodegradables and Biomimetics, University of Minho, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, AvePark, Parque de Ciência e Tecnolog

[2] ICVS/3B’s – PT Government Associate Laboratory, Braga/Guimarães

[3] Ripoll y De Prado Sports Clinic: Murcia-Madrid FIFA Medical Centre of Excellence, Madrid

[4] Orthopedic Department Centro Hospitalar Póvoa de Varzim, Vila do Conde

[5] Orthopaedic Biotechnology Laboratory, IRCCS Galeazzi Orthopaedic Institute, Milan

[6] Center of Experimental Orthopaedics, Saarland University Medical Center, Kirrbergerstr Bldg 37, Homburg/Saar

[7] Clínica do Dragão, Espregueira-Mendes Sports Centre – FIFA Medical Centre of Excellence, Porto

[8] Dom Henrique Research Centre, Porto

[9] Orthopedic Department, University of Minho, Braga

[10] The Discoveries Centre for Regenerative and Precision Medicine, Headquarters at University of Minho, Avepark, 4805-017 Barco, Guimarães

来源：

Journal of Experimental Orthopaedics | / 5卷 / 1期

关键词：

Bone; Cartilage; Clinical; Ligament; Muscle; Scaffold; Stem cells; Tendon; Translation;

D O I：

10.1186/s40634-018-0133-9

中图分类号：

学科分类号：

摘要：

Orthopaedic disorders are very frequent, globally found and often partially unresolved despite the substantial advances in science and medicine. Their surgical intervention is multifarious and the most favourable treatment is chosen by the orthopaedic surgeon on a case-by-case basis depending on a number of factors related with the patient and the lesion. Numerous regenerative tissue engineering strategies have been developed and studied extensively in laboratory through in vitro experiments and preclinical in vivo trials with various established animal models, while a small proportion of them reached the operating room. However, based on the available literature, the current strategies have not yet achieved to fully solve the clinical problems. Thus, the gold standards, if existing, remain unchanged in the clinics, notwithstanding the known limitations and drawbacks. Herein, the involvement of regenerative tissue engineering in the clinical orthopaedics is reviewed. The current challenges are indicated and discussed in order to describe the current disequilibrium between the needs and solutions made available in the operating room. Regenerative tissue engineering is a very dynamic field that has a high growth rate and a great openness and ability to incorporate new technologies with passion to edge towards the Holy Grail that is functional tissue regeneration. Thus, the future of clinical solutions making use of regenerative tissue engineering principles for the management of orthopaedic disorders is firmly supported by the clinical need. © 2018, The Author(s).

引用

共 154 条

[11]

Barber F.A., Herbert M.A., Coons D.A., Tendon augmentation grafts: biomechanical failure loads and failure patterns, Arthroscopy, 22, 5, pp. 534-538, (2006)

[12]

Basad E., Ishaque B., Bachmann G., Sturz H., Steinmeyer J., Matrix-induced autologous chondrocyte implantation versus microfracture in the treatment of cartilage defects of the knee: a 2-year randomised study, Knee Surg Sports Traumatol Arthrosc, 18, 4, pp. 519-527, (2010)

[13]

Bayon Y., Vertes A.A., Ronfard V., Egloff M., Snykers S., Salinas G.F., Thomas R., Girling A., Lilford R., Clermont G., Translating cell-based regenerative medicines from research to successful products: challenges and solutions, Tissue Eng B Rev, 20, 4, pp. 246-256, (2014)

[14]

Becher C., Laute V., Fickert S., Zinser W., Niemeyer P., John T., Diehl P., Kolombe T., Siebold R., Fay J., Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial, J Orthop Surg Res, 12, 1, (2017)

[15]

Beitzel K., Chowaniec D.M., McCarthy M.B., Cote M.P., Russell R.P., Obopilwe E., Imhoff A.B., Arciero R.A., Mazzocca A.D., Stability of double-row rotator cuff repair is not adversely affected by scaffold interposition between tendon and bone, Am J Sports Med, 40, 5, pp. 1148-1154, (2012)

[16]

Bond J.L., Dopirak R.M., Higgins J., Burns J., Snyder S.J., Arthroscopic replacement of massive, irreparable rotator cuff tears using a GraftJacket allograft: technique and preliminary results, Arthroscopy, 24, 4, (2008)

[17]

Bouyarmane H., Beaufils P., Pujol N., Bellemans J., Roberts S., Spalding T., Zaffagnini S., Marcacci M., Verdonk P., Womack M., Verdonk R., Polyurethane scaffold in lateral meniscus segmental defects: clinical outcomes at 24 months follow-up, Orthop Traumat Surg Res, 100, 1, pp. 153-157, (2014)

[18]

Brittberg M., Cell carriers as the next generation of cell therapy for cartilage repair: a review of the matrix-induced autologous chondrocyte implantation procedure, The American journal of sports medicine, 38, 6, pp. 1259-1271, (2010)

[19]

Brittberg M., Lindahl A., Nilsson A., Ohlsson C., Isaksson O., Peterson L., Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation, N Engl J Med, 331, 14, pp. 889-895, (1994)

[20]

Buchler M.W., Diener M.K., Weitz J., Scientific evaluation of modern clinical research: we need a new currency!, Langenbeck's Arch Surg, 396, 7, (2011)

← 1 2 3 4 5 6 7 8 9 10 →